OBJECTIVE: We wanted to determine the technical and clinical efficacy of using a PTFE-covered self-expandable nitinol stent for the palliative treatment of malignant biliary obstruction. MATERIALS AND METHODS: Thirty-seven patients with common bile duct strictures caused by malignant disease were treated by placing a total of 37 nitinol PTFE stents. These stents were covered with PTFE with the exception of the last 5 mm at each end; the stent had an unconstrained diameter of 10 mm and a total length of 50-80 mm. The patient survival rate and stent patency rate were calculated by performing Kaplan-Meier survival analysis. The bilirubin, serum amylase and lipase levels before and after stent placement were measured and then compared using a Wilcoxon signed-rank test. The average follow-up duration was 27.9 weeks (range: 2-81 weeks). RESULTS: Placement was successful in all cases. Seventy-six percent of the patients (28/37) experienced adequate palliative drainage for the remainder of their lives. There were no immediate complications. Three patients demonstrated stent sludge occlusion that required PTBD (percutaneous transhepatic biliary drainage) irrigation. Two patients experienced delayed stent migration with stone formation at 7 and 27 weeks of follow-up, respectively. Stent insertion resulted in acute elevations of the amylase and lipase levels one day after stent insertion in 11 patients in spite of performing endoscopic sphincterotomy (4/6). The bilirubin levels were significantly reduced one week after stent insertion (p < 0.01). The 30-day mortality rate was 8% (3/37), and the survival rates were 49% and 27% at 20 and 50 weeks, respectively. The primary stent patency rates were 85%, and 78% at 20 and 50 weeks, respectively. CONCLUSION: The PTFE-covered self-expandable nitinol stent is safe to use with acceptable complication rates. This study is similar to the previous studies with regard to comparing the patency rates and survival rates.
OBJECTIVE: We wanted to determine the technical and clinical efficacy of using a PTFE-covered self-expandable nitinol stent for the palliative treatment of malignant biliary obstruction. MATERIALS AND METHODS: Thirty-seven patients with common bile duct strictures caused by malignant disease were treated by placing a total of 37 nitinolPTFE stents. These stents were covered with PTFE with the exception of the last 5 mm at each end; the stent had an unconstrained diameter of 10 mm and a total length of 50-80 mm. The patient survival rate and stent patency rate were calculated by performing Kaplan-Meier survival analysis. The bilirubin, serum amylase and lipase levels before and after stent placement were measured and then compared using a Wilcoxon signed-rank test. The average follow-up duration was 27.9 weeks (range: 2-81 weeks). RESULTS: Placement was successful in all cases. Seventy-six percent of the patients (28/37) experienced adequate palliative drainage for the remainder of their lives. There were no immediate complications. Three patients demonstrated stent sludge occlusion that required PTBD (percutaneous transhepatic biliary drainage) irrigation. Two patients experienced delayed stent migration with stone formation at 7 and 27 weeks of follow-up, respectively. Stent insertion resulted in acute elevations of the amylase and lipase levels one day after stent insertion in 11 patients in spite of performing endoscopic sphincterotomy (4/6). The bilirubin levels were significantly reduced one week after stent insertion (p < 0.01). The 30-day mortality rate was 8% (3/37), and the survival rates were 49% and 27% at 20 and 50 weeks, respectively. The primary stent patency rates were 85%, and 78% at 20 and 50 weeks, respectively. CONCLUSION: The PTFE-covered self-expandable nitinol stent is safe to use with acceptable complication rates. This study is similar to the previous studies with regard to comparing the patency rates and survival rates.
Authors: Do Hyun Park; Myung-Hwan Kim; Jung Sik Choi; Sang Soo Lee; Dong Wan Seo; Ji Hye Kim; Jimin Han; Jong Cheol Kim; Eun Kwang Choi; Sung Koo Lee Journal: Clin Gastroenterol Hepatol Date: 2006-05-22 Impact factor: 11.382
Authors: J S Laméris; J Stoker; H G Nijs; H M Zonderland; O T Terpstra; M van Blankenstein; H E Schütte Journal: Radiology Date: 1991-06 Impact factor: 11.105
Authors: H Isayama; Y Komatsu; T Tsujino; N Sasahira; K Hirano; N Toda; Y Nakai; N Yamamoto; M Tada; H Yoshida; Y Shiratori; T Kawabe; M Omata Journal: Gut Date: 2004-05 Impact factor: 23.059
Authors: E K Salomonowitz; A Adam; F Antonucci; G Stuckmann; C L Zollikofer Journal: Cardiovasc Intervent Radiol Date: 1992 Nov-Dec Impact factor: 2.740
Authors: P Rossi; M Bezzi; M Rossi; A Adam; N Chetty; M E Roddie; V Iacari; W Cwikiel; C L Zollikofer; F Antonucci Journal: J Vasc Interv Radiol Date: 1994 Mar-Apr Impact factor: 3.464
Authors: Anthony T DeBenedet; B Joseph Elmunzer; Sean T McCarthy; Grace H Elta; Philip S Schoenfeld Journal: Am J Gastroenterol Date: 2013-07-23 Impact factor: 10.864
Authors: Sun Jun Ahn; Jae Ik Bae; Tae Sun Han; Je Hwan Won; Ji Dae Kim; Kyu-Sung Kwack; Jae Hee Lee; Young Chul Kim Journal: Korean J Radiol Date: 2012-10-12 Impact factor: 3.500
Authors: Hyun Pyo Hong; Tae-Seok Seo; In-Ho Cha; Jung Rim Yu; Young Jae Mok; Joo Hyeong Oh; Se Hwan Kwon; Sam Soo Kim; Seung Kwon Kim Journal: Korean J Radiol Date: 2013-08-30 Impact factor: 3.500
Authors: Jae Hyun Bae; Yong Hwan Kwon; Ye Chan Jung; Ji Mo Jung; Hae Beom Lee; Ki Chang Lee; Nam Soo Kim; Min-Su Kim Journal: J Vet Med Sci Date: 2013-05-14 Impact factor: 1.267